A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
NCT06151223
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC) and to facilitate the use of state-of-the-art machine learning-based algorithms that utilize databases and images with the purpose of identifying early stages of pancreatic cancer, as well as people at high-risk.The study also aims to provide a platform for development of an interventional protocol for early detection of PDAC.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Pancreatic Cancer
- Pancreatic Ductal Adenocarcinoma
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Mayo Clinic
- Last updated on ClinicalTrials.gov
- March 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Minnesota · 1
- Mayo Clinic in Rochester · Rochester, MN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.